Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļGKOS
āļāļ·āđāļāļāļĢāļīāļĐāļąāļGlaukos Corp
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 25, 2015
āļāļĩāļāļĩāđāļBurns (Thomas William)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ995
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJun 25
āļāļĩāđāļāļĒāļđāđ1 Glaukos Way
āđāļĄāļ·āļāļALISO VIEJO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX NASDAQ Basic NYSE
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ92656
āđāļāļĢāļĻāļąāļāļāđ19493679600
āđāļ§āđāļāđāļāļāđhttps://www.glaukos.com
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļGKOS
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 25, 2015
āļāļĩāļāļĩāđāļBurns (Thomas William)
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
Mr. David F. Hoffmeister
Independent Director
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Mr. Marc A. Stapley
Independent Director
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
Dr. Leana S. Wen, M.D.
Independent Director
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
Mr. David F. Hoffmeister
Independent Director
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Mr. Marc A. Stapley
Independent Director
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
Invesco S&P SmallCap Health Care ETF
Alger Weatherbie Enduring Growth ETF
State Street SPDR S&P Health Care Equipment ETF
ROBO Global Healthcare Technology & Innovation ETF
State Street SPDR S&P 600 Small Cap Growth ETF
Vanguard S&P Small-Cap 600 Growth Index Fund
iShares S&P Small-Cap 600 Growth ETF
iShares U.S. Medical Devices ETF
OneAscent Enhanced Small and Mid Cap ETF
State Street SPDR S&P SmallCap 600 ESG ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Invesco S&P SmallCap Health Care ETF
āļŠāļąāļāļŠāđāļ§āļ3.09%
Alger Weatherbie Enduring Growth ETF
āļŠāļąāļāļŠāđāļ§āļ2.07%
State Street SPDR S&P Health Care Equipment ETF
āļŠāļąāļāļŠāđāļ§āļ1.79%
ROBO Global Healthcare Technology & Innovation ETF
āļŠāļąāļāļŠāđāļ§āļ1.4%
State Street SPDR S&P 600 Small Cap Growth ETF
āļŠāļąāļāļŠāđāļ§āļ0.69%
Vanguard S&P Small-Cap 600 Growth Index Fund
āļŠāļąāļāļŠāđāļ§āļ0.65%
iShares S&P Small-Cap 600 Growth ETF
āļŠāļąāļāļŠāđāļ§āļ0.64%
iShares U.S. Medical Devices ETF
āļŠāļąāļāļŠāđāļ§āļ0.6%
OneAscent Enhanced Small and Mid Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.53%
State Street SPDR S&P SmallCap 600 ESG ETF
āļŠāļąāļāļŠāđāļ§āļ0.51%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ